Elicin Olgun, Vollnberg Bernd, Shelan Mohamed, Riggenbach Elena, Bojaxhiu Beat, Mathier Etienne, Giger Roland, Aebersold Daniel M, Klaeser Bernd
Department of Radiation Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Clin Transl Radiat Oncol. 2021 Aug 29;31:8-13. doi: 10.1016/j.ctro.2021.08.007. eCollection 2021 Nov.
Patients diagnosed with locoregionally advanced head and neck squamous cell carcinoma (LAHNSCC) regularly undergo staging with F-FDG PET/CT in our center. In cases of delays in radiotherapy (RT) planning CT more than 4 weeks after initial PET/CT or clinically suspected progress, PET/CT is repeated for restaging and as an RT planning reference. Our aim was to determine the impact of second-look PET/CT on stage migration, treatment change and RT planning.
Consequent treatment changes were categorized as minor and major. Minor changes were defined as PET/CT-based modifications of RT plans, e.g., the addition of anatomical compartments, changes in high- and low-risk dose levels or both. Major changes included changes from curative to palliative treatment intent and alterations of interdisciplinary treatment plans, such as the addition of induction chemotherapy, switch to primary surgery, no treatment and/or the necessity of additional diagnostic work-up resulting in the postponement or cancellation of treatment.
Thirty-two newly diagnosed LAHNSCC patients who were treated between 2014 and 2018 underwent second-look PET/CT (median interval 42.5 days). Second-look PET/CT led to locoregional and distant upstaging in 3/32 and 1/32 patients, respectively. In 1/32 patients (3%), second-look PET/CT led to a palliative approach with systemic treatment. New lymph node metastases were discovered in 16 patients, 6 of whom also showed significant progression of the primary tumor, resulting in minor changes in 16 of the remaining 31 patients (52%) who were treated curatively.
If RT treatment planning of LAHNSCC was delayed by more than 4 weeks after initial PET/CT staging or when progression was clinically suspected, a second look at FDG-PET/CT was performed. This led to changes in treatment planning in more than half of the cases, which is expected to directly influence oncologic outcomes.
在我们中心,被诊断为局部区域晚期头颈部鳞状细胞癌(LAHNSCC)的患者通常会接受F-FDG PET/CT分期检查。如果在首次PET/CT检查后超过4周进行放疗(RT)计划CT时出现延迟,或者临床上怀疑病情进展,则会重复进行PET/CT检查以重新分期并作为RT计划的参考。我们的目的是确定二次PET/CT检查对分期迁移、治疗改变和RT计划的影响。
后续的治疗改变分为轻微改变和重大改变。轻微改变定义为基于PET/CT的RT计划修改,例如增加解剖区域、改变高风险和低风险剂量水平或两者皆有。重大改变包括从根治性治疗意图转变为姑息性治疗意图以及跨学科治疗计划的改变,如增加诱导化疗、改为原发手术、不进行治疗和/或需要额外的诊断检查导致治疗推迟或取消。
2014年至2018年期间接受治疗的32例新诊断LAHNSCC患者接受了二次PET/CT检查(中位间隔时间为42.5天)。二次PET/CT检查分别导致3/32例患者出现局部区域分期上调和1/32例患者出现远处分期上调。在1/32例患者(3%)中,二次PET/CT检查导致采用姑息性全身治疗方法。在16例患者中发现了新的淋巴结转移,其中6例患者的原发肿瘤也有显著进展,导致其余31例接受根治性治疗的患者中有16例(52%)出现轻微改变。
如果LAHNSCC的RT治疗计划在首次PET/CT分期后延迟超过4周,或者临床上怀疑病情进展,则进行二次FDG-PET/CT检查。这导致超过半数的病例治疗计划发生改变,预计将直接影响肿瘤学结局。